Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 3918 Download: 246 Citations: 3

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 2412 Download: 258 Citations: 4

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 2360 Download: 161 Citations: 2

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 2808 Download: 183 Citations: 3

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 3321 Download: 323 Citations: 5

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 859 Download: 33

Original Article

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0004

View: 1972 Download: 152 Citations: 2

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 2204 Download: 141 Citations: 7

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun

Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0327

View: 2368 Download: 149 Citations: 2

Editorial

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 1412 Download: 44

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 1600 Download: 91

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 1507 Download: 58

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828

View: 1443 Download: 49 Citations: 2

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 5553 Download: 474 Citations: 8

Original Article

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 4554 Download: 280 Citations: 10

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 1780 Download: 52

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 3466 Download: 286 Citations: 5

Original Article

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2022;28(1):77-90. Published online November 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0188

View: 4233 Download: 122 Citations: 8

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

DOI: https://doi.org/10.3350/cmh.2020.0333

View: 3653 Download: 130 Citations: 13

Review

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0187

View: 12246 Download: 447 Citations: 16

Original Article

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0216

View: 4375 Download: 190 Citations: 18

Editorial

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 3574 Download: 120 Citations: 6

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2021;27(1):94-96. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0305

View: 3446 Download: 127 Citations: 3

Review

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon, Aileen Wee

Clin Mol Hepatol. 2021;27(1):44-57. Published online November 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0181

View: 10674 Download: 327 Citations: 31

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Emerging medical therapies for severe alcoholic hepatitis

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 4954 Download: 197 Citations: 13

Review

Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis

Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada

Clin Mol Hepatol. 2020;26(3):280-293. Published online June 4, 2020

DOI: https://doi.org/10.3350/cmh.2020.0037

View: 6483 Download: 221 Citations: 9

Original Article

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients

Waleed Seif Eldin Mohamed Mostafa, Mohammed Hassan Saiem Al-Dahr, Dalia Abdel Hamid Omran, Zeinab Fathy Abdullah, Suzan Hamdy Elmasry, Mohamed Nabil Ibrahim

Clin Mol Hepatol. 2020;26(1):60-69. Published online October 22, 2019

DOI: https://doi.org/10.3350/cmh.2019.0051

View: 5543 Download: 127 Citations: 3

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection

Hye Soo Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, Gi Hong Choi, Hyon-Suk Kim

Clin Mol Hepatol. 2020;26(1):33-44. Published online June 27, 2019

DOI: https://doi.org/10.3350/cmh.2018.0073

View: 5257 Download: 177 Citations: 14

Review

Advances in ultrasound diagnosis in chronic liver diseases

Hitoshi Maruyama, Naoya Kato

Clin Mol Hepatol. 2019;25(2):160-167. Published online February 18, 2019

DOI: https://doi.org/10.3350/cmh.2018.1013

View: 10142 Download: 459 Citations: 21

Original Article

The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study

Laura Rotundo, Alana Persaud, Mirela Feurdean, Sushil Ahlawat, Hyun-seok Kim

Clin Mol Hepatol. 2018;24(4):392-401. Published online August 2, 2018

DOI: https://doi.org/10.3350/cmh.2018.0011

View: 11370 Download: 227 Citations: 34

1 | 2 | 3 |

Viewed By 5023	A decade of liver organoids: Advances in disease modeling
Viewed By 4783	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3930	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3087	MAFLD: How is it different from NAFLD?
Viewed By 2498	Management of refractory ascites

Cited By 118	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 55	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 53	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 48	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis

Search